In an update on the U.S. Food and Drug Administration’s efforts in combatting harm from opioids, FDA commissioner Robert M. Califf, MD highlighted the recent marketing authorization of NOL technology as an innovative solution for clinicians to personalize opioid-based analgesia in anesthetized patients.
Medasense is proud to be able to offer the cutting edge NOL-Nociception Level Index® technology to help U.S. patients suffer less from pain and the adverse effects of opioid medication.
Learn more at https://www.fda.gov/news-events/fda-voices/update-fdas-overdose-prevention-framework-addressing-critical-areas-need